Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
CI 941
Known as:
CI-941
, CI941
National Institutes of Health
Create Alert
Related topics
Related topics
3 relations
Biantrazole
DuP 941
Broader (1)
losoxantrone
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin
G. R. Fisher
,
L. Patterson
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 13643480
SummaryThe MCF-7 cell S9 fraction and whole MCF-7 cells can mediate one-electron-redox cycling of doxorubicin, giving rise to…
Expand
2002
2002
The oxidative biotransformation of losoxantrone (CI-941).
U. Renner
,
G. Piperopoulos
,
R. Gebhardt
,
G. Ehninger
,
K. Zeller
Drug metabolism and disposition: the biological…
2002
Corpus ID: 7733104
The oxidative biotransformation of the anticancer drug 7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino…
Expand
1996
1996
Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
G. Chen
,
B. Teicher
,
E. Frei
Anticancer research
1996
Corpus ID: 20626202
The reversing effect of p-glycoprotein (Pgp) inhibitors on the multidrug resistance (MDR) phenotype is well established in a…
Expand
1993
1993
Detection and identification of human urinary metabolites of biantrazole (CI-941).
J. Blanz
,
U. Renner
,
K. Schmeer
,
G. Ehninger
,
K. P. Zeller
Drug metabolism and disposition: the biological…
1993
Corpus ID: 30226541
The anthrapyrazole derivative biantrazole (7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2- hydroxyethyl)amino]ethyl]amino…
Expand
1992
1992
Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation.
B. J. Foster
,
D. Newell
,
+4 authors
A. Calvert
European journal of cancer
1992
Corpus ID: 24352854
The development of new drugs in early clinical trials is currently based upon the results of preclinical antitumour and toxicity…
Expand
1992
1992
Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
M. Graham
,
D. Newell
,
B. J. Foster
,
L. Gumbrell
,
K. Jenns
,
A. Calvert
Cancer research
1992
Corpus ID: 32161013
The pharmacokinetics of the anthrapyrazole CI-941 has been investigated in conjunction with the Phase I evaluation of the drug…
Expand
Highly Cited
1991
Highly Cited
1991
Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.
D. Talbot
,
I. Smith
,
J. Mansi
,
I. Judson
,
A. Calvert
,
S. Ashley
Journal of clinical oncology : official journal…
1991
Corpus ID: 24985110
Thirty-one patients with advanced breast cancer were treated with CI941, an anthrapyrazole structurally related to mitoxantrone…
Expand
Review
1991
Review
1991
Anthrapyrazoles: true successors to the anthracyclines?
I. Judson
Anti-cancer drugs
1991
Corpus ID: 8473267
The anthrapyrazoles are a new class of intercalating agents which were synthesized in order to reduce the potential for free…
Expand
1989
1989
Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid-phase extraction and high-performance liquid chromatography.
M. Graham
,
D. Newell
,
A. Calvert
Journal of chromatography
1989
Corpus ID: 31859336
This assay has facilitated the accurate determination of the pharmacokinetics of the drug in patients treated at the phase I…
Expand
1987
1987
The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitro.
M. Graham
,
D. Newell
,
J. Butler
,
B. Hoey
,
L. Patterson
Biochemical pharmacology
1987
Corpus ID: 11443197
The anthrapyrazole CI941 is one of a new series of DNA complexing drugs which displays high level broad spectrum antitumour…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE